Stoke Therapeutics(STOK)
$27.21+-0.50 (+2.52%)
STOK
Stoke Therapeutics financials statements
$27.21
At close:+-0.50 (+2.52%)
Want to see STOK full AI Analyst Report?
Stoke Therapeutics (STOK) Ratios
478 Followers
Stoke Therapeutics Ratios
STOK's free cash flow for Q3 2026 was $-65.54M. For the 2026 fiscal year, STOK's free cash flow was decreased by $-2.85M and operating cash flow was $-62.69M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.28 | 5.81 | 6.99 | 7.77 | 13.37 |
| Quick Ratio | 5.28 | 5.81 | 6.99 | 7.77 | 13.37 |
| Cash Ratio | 1.46 | 3.20 | 6.21 | 3.62 | 8.45 |
| Solvency Ratio | -0.08 | -2.04 | -1.49 | -1.40 | -4.02 |
| Operating Cash Flow Ratio | 0.79 | -2.17 | -2.63 | -1.02 | -3.90 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 239.72M | $ 190.22M | $ 146.56M | $ 172.85M | $ 208.13M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.19 | 1.19 | 1.43 | 1.39 | 1.10 |
| Debt Service Coverage Ratio | -568.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -2287.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.04 | 0.05 | 0.06 | 0.04 |
| Net Debt to EBITDA | 15.88 | 1.45 | 1.69 | 1.08 | 1.69 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| EBIT Margin | -3.73% | -243.42% | -1307.21% | -841.24% | 0.00% |
| EBITDA Margin | -2.77% | -237.46% | -1279.09% | -828.78% | 0.00% |
| Operating Profit Margin | -11.16% | -277.31% | -1307.21% | -841.24% | 0.00% |
| Pretax Profit Margin | -3.73% | -243.42% | -1192.47% | -814.73% | 0.00% |
| Net Profit Margin | -3.73% | -243.42% | -1192.47% | -814.73% | 0.00% |
| Continuous Operations Profit Margin | -3.73% | -243.42% | -1192.47% | -814.73% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 33.44% | 87.78% | 91.22% | 96.85% | 99.70% |
| Return on Assets (ROA) | -1.65% | -32.77% | -45.85% | -39.47% | -35.92% |
| Return on Equity (ROE) | -1.95% | -38.85% | -65.62% | -54.68% | -39.40% |
| Return on Capital Employed (ROCE) | -5.71% | -43.79% | -58.11% | -46.45% | -38.82% |
| Return on Invested Capital (ROIC) | -5.66% | -43.35% | -57.51% | -45.97% | -38.55% |
| Return on Tangible Assets | -1.65% | -32.77% | -45.85% | -39.47% | -35.92% |
| Earnings Yield | -0.37% | -14.94% | -45.24% | -28.15% | -9.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 23.33 | 52.22 | 137.19 | 21.10 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 29.52 | 4.43 | 0.71 | 1.09 | 0.00 |
| Asset Turnover | 0.44 | 0.13 | 0.04 | 0.05 | 0.00 |
| Working Capital Turnover Ratio | 0.84 | 0.19 | 0.04 | 0.06 | 0.00 |
| Cash Conversion Cycle | 15.65 | 6.99 | 2.66 | 17.30 | 0.00 |
| Days of Sales Outstanding | 15.65 | 6.99 | 2.66 | 17.30 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 15.65 | 6.99 | 2.66 | 17.30 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.77 | -1.61 | -1.84 | -0.82 | -1.82 |
| Free Cash Flow Per Share | 0.76 | -1.61 | -1.88 | -0.92 | -1.85 |
| Dividend Paid and CapEx Coverage Ratio | 68.04 | -427.84 | -50.17 | -8.04 | -55.76 |
| Capital Expenditure Coverage Ratio | 68.04 | -427.84 | -50.17 | -8.04 | -55.76 |
| Operating Cash Flow Coverage Ratio | 15.16 | -37.40 | -39.31 | -13.51 | -44.40 |
| Operating Cash Flow to Sales Ratio | 0.25 | -2.38 | -9.23 | -2.57 | 0.00 |
| Free Cash Flow Yield | 2.39% | -14.61% | -35.73% | -9.98% | -7.73% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -264.50 | -6.68 | -2.21 | -3.55 | -10.27 |
| Price-to-Sales (P/S) Ratio | 10.19 | 16.30 | 26.36 | 28.94 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.33 | 2.60 | 1.45 | 1.94 | 4.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 41.85 | -6.84 | -2.80 | -10.02 | -12.94 |
| Price-to-Operating Cash Flow Ratio | 41.23 | -6.86 | -2.85 | -11.27 | -13.17 |
| Price-to-Earnings Growth (PEG) Ratio | 2.85 | 0.22 | 0.26 | -0.32 | -0.21 |
| Enterprise Value Multiple | -351.59 | -5.42 | -0.37 | -2.41 | -8.67 |
| Enterprise Value | 1.80B | 470.06M | 42.03M | 247.83M | 737.99M |
| EV to EBITDA | -351.59 | -5.42 | -0.37 | -2.41 | -8.67 |
| EV to Sales | 9.75 | 12.86 | 4.79 | 19.98 | 0.00 |
| EV to Free Cash Flow | 40.04 | -5.40 | -0.51 | -6.92 | -10.84 |
| EV to Operating Cash Flow | 39.45 | -5.41 | -0.52 | -7.78 | -11.03 |
| Tangible Book Value Per Share | 5.95 | 4.24 | 3.63 | 4.75 | 5.93 |
| Shareholders’ Equity Per Share | 5.95 | 4.24 | 3.63 | 4.75 | 5.93 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 3.11 | 0.68 | 0.20 | 0.32 | 0.00 |
| Net Income Per Share | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.91 | 0.97 | 1.00 |
| Research & Development to Revenue | 0.75 | 2.44 | 9.37 | 6.27 | 0.00 |
| SG&A to Revenue | 0.36 | 1.33 | 4.71 | 3.14 | 0.00 |
| Stock-Based Compensation to Revenue | 0.17 | 0.75 | 2.88 | 1.84 | 0.00 |
| Income Quality | -6.62 | 0.98 | 0.77 | 0.32 | 0.78 |
Currency in USD
